Human Pathology
Volume 34, Issue 1 , Pages 54-64 , January 2003

Parathyroid neoplasms: Clinical, histopathological, and tissue microarray-based molecular analysis

,Accepted 16 April 2002.

References 

  1. Koea JB, Shaw JH. Parathyroid cancer: Biology and management. Surg Oncol. 1999;8:155–165
  2. Ghandur-Mnaymneh L, Kimura N. The parathyroid adenoma: A histopathologic definition with a study of 172 cases of primary hyperparathyroidism. Am J Pathol. 1984;115:70–83
  3. Schantz A, Castleman B. Parathyroid carcinoma: A study of 70 cases. Cancer. 1973;31:600–605
  4. DeLellis R. Tumors of the parathyroid gland. In:  Rosai J,  Sobin L editor. Atlas of Tumor Pathology (3rd series, Fascicle-6). Washington, DC: Armed Forces Institute of Pathology:; 1993;
  5. Abbona GC, Papotti M, Gasparri G, et al.  Proliferative activity in parathyroid tumors as detected by Ki-67 immunostaining. Hum Pathol. 1995;26:135–138
  6. Vargas MP, Vargas HI, Kleiner DE, et al.  The role of prognostic markers (MIB-1, RB, and bcl-2) in the diagnosis of parathyroid tumors. Mod Pathol. 1997;10:12–17
  7. Erickson LA, Jin L, Wollan P, et al.  Parathyroid hyperplasia, adenomas, and carcinomas: Differential expression of p27 protein. Am J Surg Pathol. 1999;23:288–295
  8. Vasef MA, Brynes RK, Sturm M, et al.  Expression of cyclin D1 in parathyroid carcinomas, adenomas, and hyperplasias: A paraffin immunohistochemical study. Mod Pathol. 1999;12:412–416
  9. Naccarato AG, Marcocci C, Miccoli P, et al.  Bcl-2, p53 and MIB-1 expression in normal and neoplastic parathyroid tissues. J Endocrinol Invest. 1998;21:136–141
  10. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature. 1991;351:453–456
  11. Cordon-Cardo C. Mutation of cell cycle regulators: Biological and clinical implications for human neoplasia. Am J Pathol. 1997;147:545–560
  12. Buglioni S, D'Agnano I, Cosimelli M, et al.  Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: Independent prognostic role of p53 and Bcl-2. Int J Cancer. 1999;84:545–552
  13. Wang W, Johansson H, Kvasnicka T, et al.  Detection of apoptotic cells and expression of Ki-67 antigen, Bcl-2, p53 oncoproteins in human parathyroid adenoma. APMIS. 1996;104:789–796
  14. Hoos A, Urist MJ, Stojadinovic A, et al.  Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol. 2001;158:1245–1251
  15. Kononen J, Bubendorf L, Kallioniemi A, et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844–847
  16. Altman DG. Describing data. In:  Altman DG editors. Practical Statistics for Medical Research. London: Chapman and Hall; 1996;p. 404–408
  17. Mehta C, Patel N. A network algorithm for performing Fisher's exact test in rXc contingency tables. J Am Stat Assoc. 1983;78:427–434
  18. Fisher RA, Yates F. Statistical Tables for Biological, Agricultural and Medical Research. ed 6. Edinburgh: Oliver & Boyd; 1964; Appendix B
  19. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc. 1958;53:457–481
  20. Peto R, Peto J. Asymptotically efficient rank invariant procedures. J R Stat Soc A. 1972;135:185–207
  21. Snover DC, Foukar K. Mitotic activity in benign parathyroid disease. Am J Clin Pathol. 1981;75:345–347
  22. San Juan J, Monteagudo C, Fraker D, et al.  Significance of mitotic activity and other morphologic parameters in parathyroid adenomas: Correlation with clinical behavior. Am J Clin Pathol. 1989;92:523; (abstr)
  23. Kishikawa S, Shan L, Ogihara K, et al.  Overexpression and genetic abnormality of p53 in parathyroid adenomas. Pathol Int. 1999;49:853–857
  24. Karak AK, Sarkar S, Chumber S, et al.  MIB-1 proliferative index in parathyroid adenoma and hyperplasia. Indian J Med Res. 1997;105:235–238
  25. Hsi ED, Zuckerburg LR, Yang W, et al.  Cyclin D1/PRAD1 expression in parathyroid adenomas: An immunohistochemical study. J Clin Endocrinol Metab. 1996;81:1736–1739
  26. Kameyama K, Takami H, Umemura S, et al.  PCNA and Ki-67 as prognostic markers in human parathyroid carcinomas. Ann Surg Oncol. 2000;7:301–305
  27. Hakim JP, Levine MA. Absence of p53 point mutations in parathyroid adenomas and carcinomas. J Clin Endocrinol Metab. 1994;78:103–106
  28. Zhang H, Xeong Y, Beach D. Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol Biol Cell. 1993;4:897–906
  29. Ogawa M, Maeda K, Onoda N, et al.  Loss of p21WAF1/DIP1 expression correlates with disease progression in gastric carcinoma. Br J Cancer. 1997;75:1617–1620
  30. Zirbes TK, Baldus SE, Moeing SP, et al.  Prognostic impact of p21/waf1/cip1 in colorectal cancer. Int J Cancer. 2000;89:14–18
  31. Stein JP, Ginsberg DA, Grossfeld GD, et al.  Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst. 1998;90:1072–1079
  32. Chao DT, Korsmayer SJ. Bcl-2 family: Regulators of cell death. Ann Rev Immunol. 1998;16:395–419
  33. Fero ML, Rivkin M, Tasch M, et al.  A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27 (Kip1)-deficient mice. Cell. 1996;85:733–744
  34. Hemmer S, Wasenius VM, Haglund C, et al.  Deletion of 11q23 and cyclin D1 overexpression are frequent aberrations in parathyroid adenomas. Am J Pathol. 2001;158:1355–1362
  35. Hoos A, Lewis JJ, Antonescu CR, et al.  Characterization of molecular abnormalities in human fibroblastic neoplasms—A model for genotype-phenotype association in soft tissue tumors. Cancer Res. 2001;61:3171–3175
  36. Vetto JT, Brennan MF, Woodruff JM, et al.  Parathyroid carcinoma: Diagnosis and clinical history. Surgery. 1993;114:882–892
  37. Flye MW, Brennan MF. Surgical resection of metastatic parathyroid carcinoma. Ann Surg. 1981;193:425–435

PII: S0046-8177(03)00010-8

doi: 10.1053/hupa.2003.55

Human Pathology
Volume 34, Issue 1 , Pages 54-64 , January 2003

Article Tools

* Image Usage & Resolution